AR086865A1 - Metodos y composiciones para el tratamiento del cancer de cerebro - Google Patents
Metodos y composiciones para el tratamiento del cancer de cerebroInfo
- Publication number
- AR086865A1 AR086865A1 ARP120102029A ARP120102029A AR086865A1 AR 086865 A1 AR086865 A1 AR 086865A1 AR P120102029 A ARP120102029 A AR P120102029A AR P120102029 A ARP120102029 A AR P120102029A AR 086865 A1 AR086865 A1 AR 086865A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nr5r6
- treatment
- brain cancer
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composiciones y sus usos para el tratamiento del cáncer de cerebro con compuestos de ciclohexenona.Reivindicación 1: El uso de un compuesto que tiene la estructura de fórmula (1) caracterizado porque es en la preparación de un medicamento para el tratamiento de cáncer cerebral, donde cada uno de X e Y independientemente es oxígeno, NR5 o azufre; R es un hidrógeno o C(=O)alquilo C1-8; cada uno de R1, R2 y R3 independientemente es un hidrógeno, metilo o (CH2)m-CH3; R4 es NR5R6, OR5, OC(=O)R7, C(=O)OR5, C(=O)R5, C(=O)NR5R6, halógeno, lactona de 5 ó 6 miembros, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo, glucosilo, donde la lactona de 5 ó 6 miembros, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo, y glucosilo se sustituyen opcionalmente con uno o más sustituyentes seleccionados entre NR5R6, OR5, OC(=O)R7, C(=O)OR5, C(=O)R5, C(=O)NR5R6, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, y haloalquilo C1-8; cada uno de R5 y R6 es independientemente un hidrógeno o alquilo C1-8; R7 es un alquilo C1-8, OR5 o NR5R6; m = 1 - 12; y n = 1 - 12; o una sal aceptable farmacéuticamente, metabolito, solvato o prodroga del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161495875P | 2011-06-10 | 2011-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086865A1 true AR086865A1 (es) | 2014-01-29 |
Family
ID=47296743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102029A AR086865A1 (es) | 2011-06-10 | 2012-06-07 | Metodos y composiciones para el tratamiento del cancer de cerebro |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130158113A1 (es) |
| EP (1) | EP2717865A4 (es) |
| JP (1) | JP2014522411A (es) |
| KR (1) | KR20140102599A (es) |
| CN (1) | CN103796647A (es) |
| AR (1) | AR086865A1 (es) |
| AU (1) | AU2012267893A1 (es) |
| CA (1) | CA2837563A1 (es) |
| MX (1) | MX2013014488A (es) |
| TW (1) | TW201249426A (es) |
| WO (1) | WO2012170720A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI597061B (zh) * | 2013-02-20 | 2017-09-01 | 國鼎生物科技股份有限公司 | 治療白血病之方法及組成物 |
| TWI612026B (zh) * | 2013-02-20 | 2018-01-21 | 國鼎生物科技股份有限公司 | 環己烯酮組成物及其製造方法 |
| US20150018296A1 (en) * | 2013-03-15 | 2015-01-15 | Golden Biotechnology Corporation | Therapeutic methods and compositions utilizing cyclohexenone compounds |
| US9604894B2 (en) * | 2014-01-22 | 2017-03-28 | National Dong Hwa University | Compounds from antrodia camphorate and their use in treatment of diabetes mellitus |
| WO2016107582A1 (en) * | 2014-12-30 | 2016-07-07 | Oneness Biotech Co., Ltd. | Compounds from antrodia camphorata, method for preparing the same and use thereof |
| TWI734934B (zh) * | 2018-09-18 | 2021-08-01 | 麗豐實業股份有限公司 | 含４-乙醯基-安卓奎諾-ｂ之組合物用於製備抑制腦癌細胞或腦癌幹細胞生長之藥物的用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874290A (en) * | 1996-11-08 | 1999-02-23 | Northwest Biotherapeutics, Llc | Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon |
| US20070116787A1 (en) * | 2005-11-21 | 2007-05-24 | Chih-Jung Yao | Cancer treatment |
| TW200829234A (en) * | 2007-01-08 | 2008-07-16 | Golden Biotechnology Corp | Antrodia camphorata isophorone extract |
| TW200841883A (en) * | 2007-04-20 | 2008-11-01 | Microbio Company Ltd Taiwan | Composition for prevention and/or treatment of cancer |
| TW201102075A (en) * | 2009-07-09 | 2011-01-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of pancreatic cancer |
| TW201102076A (en) * | 2009-07-09 | 2011-01-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea suppressing growth of tumor cell of osteosarcoma |
| TW201109023A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of colorectal cancer |
| TWI383791B (zh) * | 2009-09-09 | 2013-02-01 | 國鼎生物科技股份有限公司 | Used to inhibit the growth of gastric cancer tumor cells of the male antler ketone compounds |
| TW201109014A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of skin cancer |
| TWI394566B (zh) * | 2009-09-09 | 2013-05-01 | 國鼎生物科技股份有限公司 | Used to inhibit the growth of ovarian cancer tumor cells of the cattle camphor cyclohexene ketone compounds |
| TW201109024A (en) * | 2009-09-09 | 2011-03-16 | Golden Biotechnology Corp | Cyclohexenone compound of Antrodia cinnomomea that suppresses growth of tumor cell of bladder cancer |
| TWI383790B (zh) * | 2009-09-09 | 2013-02-01 | 國鼎生物科技股份有限公司 | Used to inhibit the growth of oral cancer cells of the cattle Antrodylcyclohexenone compounds |
| EP2329816B1 (en) * | 2009-11-26 | 2016-04-13 | National Taiwan University | An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof |
-
2012
- 2012-06-07 KR KR1020137034366A patent/KR20140102599A/ko not_active Withdrawn
- 2012-06-07 MX MX2013014488A patent/MX2013014488A/es unknown
- 2012-06-07 CA CA2837563A patent/CA2837563A1/en not_active Abandoned
- 2012-06-07 WO PCT/US2012/041401 patent/WO2012170720A2/en not_active Ceased
- 2012-06-07 EP EP12797582.9A patent/EP2717865A4/en not_active Withdrawn
- 2012-06-07 CN CN201280039100.4A patent/CN103796647A/zh active Pending
- 2012-06-07 JP JP2014514851A patent/JP2014522411A/ja active Pending
- 2012-06-07 US US13/491,495 patent/US20130158113A1/en not_active Abandoned
- 2012-06-07 AR ARP120102029A patent/AR086865A1/es unknown
- 2012-06-07 TW TW101120444A patent/TW201249426A/zh unknown
- 2012-06-07 AU AU2012267893A patent/AU2012267893A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013014488A (es) | 2014-03-27 |
| KR20140102599A (ko) | 2014-08-22 |
| EP2717865A2 (en) | 2014-04-16 |
| US20130158113A1 (en) | 2013-06-20 |
| CN103796647A (zh) | 2014-05-14 |
| WO2012170720A3 (en) | 2013-04-11 |
| CA2837563A1 (en) | 2012-12-13 |
| TW201249426A (en) | 2012-12-16 |
| EP2717865A4 (en) | 2014-11-12 |
| WO2012170720A2 (en) | 2012-12-13 |
| AU2012267893A1 (en) | 2013-12-19 |
| JP2014522411A (ja) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR083026A1 (es) | Derivados de ciclohexenona y composiciones para el tratamiento del cancer de pulmon | |
| AR085893A1 (es) | Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos | |
| MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR086865A1 (es) | Metodos y composiciones para el tratamiento del cancer de cerebro | |
| SV2016005229A (es) | Inhibidores de syk | |
| PE20181348A1 (es) | PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y METODO DE USO | |
| UY29503A1 (es) | Derivados de amida sustituida y metodos de uso | |
| ES2770058T3 (es) | Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante | |
| AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
| CR20140294A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| UY35377A (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| AR085602A1 (es) | Inhibidores de quinasas, composiciones farmaceuticas y su aplicacion en el tratamiento de canceres y trastornos autoinmunes | |
| DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| ECSP14013215A (es) | Compuestos novedosos | |
| AR083798A1 (es) | Inhibidores selectivos de glucosidasas y sus usos | |
| CU20130116A7 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| CO2019004978A2 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| AR097545A1 (es) | COMPUESTOS A BASE DE PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |